<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01328132</url>
  </required_header>
  <id_info>
    <org_study_id>10-287-BMA</org_study_id>
    <nct_id>NCT01328132</nct_id>
  </id_info>
  <brief_title>Effect of Hyperoncotic Albumin on Vascular Hemodynamics and Oxygen Delivery Following Orthotopic Liver Transplant</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McGill University Health Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this study is to assess the effect of hyperoncotic albumin on vascular
      hemodynamics and oxygen delivery after orthotopic liver transplant. The secondary aim is to
      try to identify the dominant physiological mechanism so that we will be able to better
      identify patients that may benefit from the use of albumin (25%) boluses in addition to
      standard care in patients following liver transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">October 2011</completion_date>
  <primary_completion_date type="Anticipated">October 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac index (CI)</measure>
    <time_frame>60 minutes after the infusion of the fluid</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac function response</measure>
    <time_frame>30 and 60 minutes after the infusion of the fluid</time_frame>
    <description>An improvement in Q due primarily to a change in cardiac function should have an increase in Q of â‰¥ 0.3 ml/min/m2/mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A decrease in leak and plasma expansion</measure>
    <time_frame>30 and 60 minutes after the infusion of the fluid</time_frame>
    <description>A decrease in leak and plasma expansion will be determined by the Harrison formula for calculating a change in plasma volume from the change in Hb and change in Hct</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac output response</measure>
    <time_frame>30 and 60 minutes after the infusion of the fluid</time_frame>
    <description>Cardiac output response primarily due to a &quot;volume effect&quot; would be expected to have an increase of CVP of a minimum of 2 mmHg and an increase in CI of &gt; 0.3 L/min/m2 per mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detoxification effect of albumin</measure>
    <time_frame>30 and 60 minutes after infusion</time_frame>
    <description>A increase in vascular tone will be identified by an increase in systemic vascular resistance or a rise in blood pressure without a change in cardiac output or a rise in blood pressure with a fall in cardiac output</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Other Complications of Liver Transplant</condition>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>25% albumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>100 ml of saline will be given in addition to the standard of care every 8 hours for 24 hours.</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>25% albumin</intervention_name>
    <description>100 ml of 25% albumin will be given in addition to the standard of care every 8 hours for 24 hours</description>
    <arm_group_label>25% albumin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older

          -  Patients from the Critical care Unit

          -  Patients with a pulmonary artery occlusion catheter Inclusion:patients immediately
             following liver transplantation

        Exclusion Criteria:

          -  Patients not giving informed consent

          -  Patients who have received &gt; 300 ml of albumin within 24 hours prior to inclusion

          -  Patients known to have previous adverse reaction to human albumin solution

          -  Patients who have religious restriction to receive human blood products

          -  Patient who have initial graft failure

          -  Patients with fluctuating hemodynamics

          -  Concerns of the treating surgeon
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sheldon Magder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University Health Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sheldon Magder, MD</last_name>
    <phone>514-934-1934</phone>
    <phone_ext>35253</phone_ext>
    <email>sheldon.magder@muhc.mcgill.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Lescot, MD, PhD</last_name>
    <phone>514-934-1934</phone>
    <phone_ext>36736</phone_ext>
    <email>thomas.lescot@mail.mcgill.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2011</study_first_submitted>
  <study_first_submitted_qc>March 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2011</study_first_posted>
  <last_update_submitted>March 31, 2011</last_update_submitted>
  <last_update_submitted_qc>March 31, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>Sheldon Magder, MD</name_title>
    <organization>McGill University Health Center</organization>
  </responsible_party>
  <keyword>Liver</keyword>
  <keyword>transplant</keyword>
  <keyword>albumin</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

